Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divozilimab vs Teriflunomide in Relapsing Multiple Sclerosis
NCT05385744Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Apr 2021
- Primary completion
- Sep 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of Divozilimab in multiple sclerosis (MS), sponsored by BIOCAD. Started Apr 2021; status: completed.
02
Drugs
Divozilimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05385744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05385744.